<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075529</url>
  </required_header>
  <id_info>
    <org_study_id>KSPH-2007-16</org_study_id>
    <nct_id>NCT01075529</nct_id>
  </id_info>
  <brief_title>Early Prediction of Fluoxetine Response</brief_title>
  <official_title>Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Kai-Suan Psychiatric Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Kai-Suan Psychiatric Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify what degree of symptom changes during the early
      weeks could be used to predict eventual nonresponse at week 6 among depressive inpatients
      taking fluoxetine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with major depressive disorder will receive 20 mg/day of fluoxetine for six weeks.
      Symptom severity was assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17) at
      weeks 0, 1, 2, 3, 4 and 6. Stable response is defined as a reduction of 50% or more of the
      HAMD-17 score at week 4 and week 6 of treatment. Receiver operating characteristic curve will
      be used to determine the cutoff point of the percentage of HAMD-17 score reduction between
      stable responders and nonresponders at weeks 1, 2, 3 and 4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stable response was defined as a reduction of 50% or more of the HAMD-17 score at week 4 and week 6 of treatment</measure>
    <time_frame>6 weeks after initiation of fluxetine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI, GAF, Zung's Depression Scale, Short-Form 36, auditory evoked potential, psychomotor speed</measure>
    <time_frame>6 weeks after initiation of fluxetine</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>fluoxetine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluoxetine</intervention_name>
    <description>fluoxetine 20 mg/d</description>
    <arm_group_label>fluoxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of major depressive disorder

          -  HAM-D-17 â‰§17

          -  written informed consent

        Exclusion Criteria:

          -  Comorbid of substance abuse/dependence

          -  Comorbid with mental disorders due to general medical conditions

          -  Past history of treatment-resistant depression

          -  Severe physical problems

          -  pregnant women

          -  lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Hua Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kai-Suan Psychiatric Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kai-Suan Psychiatric Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>802</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol. 1994 Winter;9(4):245-50.</citation>
    <PMID>7868846</PMID>
  </results_reference>
  <results_reference>
    <citation>Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol. 2001 Dec;4(4):337-45.</citation>
    <PMID>11806859</PMID>
  </results_reference>
  <results_reference>
    <citation>Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004 Mar;29(3):566-79.</citation>
    <PMID>14627997</PMID>
  </results_reference>
  <results_reference>
    <citation>Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, Alpert JE. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005 Mar;20(2):87-91.</citation>
    <PMID>15729083</PMID>
  </results_reference>
  <results_reference>
    <citation>Trivedi MH, Morris DW, Grannemann BD, Mahadi S. Symptom clusters as predictors of late response to antidepressant treatment. J Clin Psychiatry. 2005 Aug;66(8):1064-70.</citation>
    <PMID>16086624</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <last_update_submitted>February 24, 2010</last_update_submitted>
  <last_update_submitted_qc>February 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ching-Hua Lin, M.D.</name_title>
    <organization>Kaohsiung Kai-Suan Psychiatric Hospital</organization>
  </responsible_party>
  <keyword>major depressive disorder, fluoxetine, Hamilton Rating Scale for Depression (HAM-D-17)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

